• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2016 Fiscal Year Final Research Report

Creation and evaluation of tetraplex DNA specific molecules aiming at anti-cancer drug with low side effect

Research Project

  • PDF
Project/Area Number 15K13748
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Bio-related chemistry
Research InstitutionKyushu Institute of Technology

Principal Investigator

Takenaka Shigeori  九州工業大学, 大学院工学研究院, 教授 (60188208)

Co-Investigator(Renkei-kenkyūsha) UTO Yoshihiro  徳島大学, ソシオテクノサイエンス研究部, 教授 (20304553)
Research Collaborator ISLAM Md. Monirul  
ESAKI Yugo  
TAKENAKA Fuminori  
MINEMATSU Hiroki  
SHINOZAKI Shingo  
KAJIMA Atsuhito  
HAMANAKA Hisashi  
KUROSE Yui  
SHINJO Akina  
SAMESHIMA Shino  
TANAKA Masami  
TAKEUCHI Ryusuke  
WAKAHARA Daiki  
Project Period (FY) 2015-04-01 – 2017-03-31
Keywords4本鎖DNA / 環状ナフタレンジイミド / 抗癌剤 / テロメアDNA
Outline of Final Research Achievements

To develop an anti-cancer drug without side-effect, a series of cyclic naphthalene diimide (cNDI) derivatives was synthesized and studied their interactions with teraplex DNAs (tDNA) using spectrophotometric and isothermal titration calorimetric technique with telomerase and growth inhibition assay of cancer cell. cNDIs carrying none-aromatic moiety have a high preference for tDNA over duplex one (dsDNA). However, their binding affinity and stabilization effect for tDNA is not enough for use of anticancer drug. On the other hand, cNDIs carrying aromatic moiety have high binding affinity for tDNA and, however, their preference for tDNA over dsDNA is not enough because of their interaction for dsDNA. The affinity of cNDIs for tDNA was correlated with telomerase and growth inhibition assay of cancer cell. These results suggested that cNDI open new concept to design anti-cancer drug with diminished side effect.

Free Research Field

核酸化学

URL: 

Published: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi